Prospective clinical investigation of the efficacy of combination radiotherapy with immune checkpoint inhibition.
暂无分享,去创建一个
[1] N. Wolmark,et al. Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. , 2021, JAMA oncology.
[2] N. Sanfilippo,et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. , 2021, The Lancet. Oncology.
[3] R. Bell,et al. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma , 2021, Journal for ImmunoTherapy of Cancer.
[4] A. Murphy,et al. Sequence of αPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses , 2021, Science Immunology.
[5] J. Ajani,et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. , 2021, The New England journal of medicine.
[6] K. Harrington,et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. , 2021, The Lancet. Oncology.
[7] Emily M. Thrash,et al. A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer , 2021, Clinical Cancer Research.
[8] U. Dafni,et al. Progression-free and overall survival for concurrent nivolumab with standard concurrent chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: Results from the European Thoracic Oncology Platform NICOLAS phase II trial (ETOP 6-14). , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[9] Joe Y. Chang,et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. , 2020, The Lancet. Respiratory medicine.
[10] R. Weichselbaum,et al. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial , 2020, Clinical Cancer Research.
[11] Joe Y. Chang,et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial , 2020, Journal for ImmunoTherapy of Cancer.
[12] T. Meirson,et al. Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors , 2020, JAMA network open.
[13] R. Tishler,et al. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. , 2020, JAMA oncology.
[14] N. Lee,et al. Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] N. Agarwal,et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. , 2020, European urology.
[16] M. Loda,et al. Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung , 2020, Journal for ImmunoTherapy of Cancer.
[17] P. Thompson,et al. Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. V. van Zelm,et al. Stereotactic radiotherapy combined with immunotherapy against metastatic melanoma: Long term results of a phase I clinical trial. , 2020, International journal of radiation oncology, biology, physics.
[19] W. Urba,et al. Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma , 2020, Journal for immunotherapy of cancer.
[20] Z. Morris,et al. Priming and Propagating Anti-tumor Immunity: Focal Hypofractionated Radiation for in Situ Vaccination and Systemic Targeted Radionuclide Theranostics for Immunomodulation of Tumor Microenvironments. , 2020, Seminars in radiation oncology.
[21] C. Simone,et al. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial. , 2020, JAMA oncology.
[22] E. Winer,et al. A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. , 2020, Clinical breast cancer.
[23] H. McArthur,et al. A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple‐negative breast cancer , 2019, Cancer.
[24] S. Jolly,et al. A Pilot Study of Atezolizumab plus Hypofractionated Image-guided Radiotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer. , 2019, International journal of radiation oncology, biology, physics.
[25] Minetta C. Liu,et al. A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer. , 2019, Thyroid : official journal of the American Thyroid Association.
[26] J. Aerts,et al. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.
[27] C. Langer,et al. Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial. , 2019, JAMA oncology.
[28] H. Horlings,et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial , 2019, Nature Medicine.
[29] Vinay Prasad,et al. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs , 2019, JAMA network open.
[30] E. Goetghebeur,et al. Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. , 2019, European urology.
[31] B. Neel,et al. Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer , 2019, Oncotarget.
[32] S. Markovina,et al. Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities. , 2019, Brachytherapy.
[33] S. Loi,et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] C. Brennan,et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.
[35] E. Wherry,et al. A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours , 2018, British Journal of Cancer.
[36] D. Planchard,et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.
[37] R. Emerson,et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade , 2018, Nature Medicine.
[38] J. Welsh,et al. Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials. , 2018, International journal of radiation oncology, biology, physics.
[39] R. Huddart,et al. Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer. , 2018, International journal of radiation oncology, biology, physics.
[40] B. Mahal,et al. Safety of combining radiotherapy with immune-checkpoint inhibition , 2018, Nature Reviews Clinical Oncology.
[41] B. Comin-Anduix,et al. Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer , 2018, Clinical Cancer Research.
[42] J. Hesser,et al. Using immunotherapy to boost the abscopal effect , 2018, Nature Reviews Cancer.
[43] Manish R. Sharma,et al. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] E. Goetghebeur,et al. Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic Melanoma. , 2017, International journal of radiation oncology, biology, physics.
[45] Tarek Mekhail,et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[46] P. Stephens,et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.
[47] S. Formenti,et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. , 2017, The Lancet. Oncology.
[48] F. Hodi,et al. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. , 2017, International journal of radiation oncology, biology, physics.
[49] S. Demaria,et al. Barriers to Radiation-Induced In Situ Tumor Vaccination , 2017, Front. Immunol..
[50] Ralph R. Weichselbaum,et al. Radiotherapy and immunotherapy: a beneficial liaison? , 2017, Nature Reviews Clinical Oncology.
[51] James J. Evans,et al. Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases. , 2016, International journal of radiation oncology, biology, physics.
[52] C. Drake,et al. Does Prophylactic Nodal Irradiation Inhibit Potential Synergy Between Radiation Therapy and Immunotherapy , 2016 .
[53] Joe Y. Chang,et al. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells , 2016, Clinical Cancer Research.
[54] S. Swetter,et al. A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. , 2015, International journal of radiation oncology, biology, physics.
[55] C. Drake,et al. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. , 2015, The Lancet. Oncology.
[56] Joe Y. Chang,et al. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. , 2015, Cancer treatment reviews.
[57] H. Ishwaran,et al. Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.
[58] N. Agarwal,et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.
[59] S. Demaria,et al. An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer , 2013, Cancer Immunology Research.
[60] Y. Yamada,et al. Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma , 2013, Cancer Immunology Research.
[61] Jedd D. Wolchok,et al. Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.
[62] Joe Y. Chang,et al. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC , 2020 .
[63] A. Al-Mamgani,et al. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[64] F. Saad,et al. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.